Abstract 2259P
Background
Type I polarized macrophages (M1) play an anti-tumor role in the tumor microenvironment (TME), and more M1 infiltration means better prognosis. Previous studies have developed algorithms to predict the fraction of M1 based on transcriptomic data, whereas few study focus on DNA methylation data.
Methods
A macrophage multiplex immunofluorescence (mIF) panel (including DAPI, panCK, CD68, CD86, IRF5, CD163 and CD206) and DNA methylation sequencing were used in lung adenocarcinoma (LUAD) patients’ formalin-fixed paraffin-embedded samples. The fraction of M1 (with more positive M1 markers [CD86 and IRF5] than M2 markers [CD163 and CD206]) was calculated based on all macrophages (DAPI+panCK-CD68+). Patients were randomly divided into training cohort (70%) and test cohort (30%). The Pearson correlation and random forest algorithm were used to screened genes to build artificial neural network (ANN) models in the training cohort. Three hundred times of three-fold cross validation were performed to obtain 900 ANN models and test the accuracy of them. The final predicted value of the ANN system were equal to the weighted average of output values of all 900 ANN models. Finally, the accuracy of the ANN system was tested validated in the test cohort.
Results
Forty patients with LUAD were enrolled, and the median fraction of M1 was 3.27% (range: 0% to 30.91%). A total of 43 genes were with p-value < 0.001 were selected by Pearson correlation, and the top eight genes (C10orf90, ITGAX, TMED9, RGN, CENPF, LGI4, PPCS and KIAA1211) from random forest algorithm were used to build 900 three-layer ANN models. Each ANN model had eight input nodes, five hidden nodes and one output node. The frequency of ANN model whose weight > 0.70 (the accuracy > 0.70) was 74.78% (673/900). The Pearson correlation coefficient between the predicted value and the true M1 fraction was 0.89 (R2 = 0.79, p < 0.01) in the training cohort and 0.80 (R2 = 0.65, p < 0.01) in the test cohort.
Conclusions
DNA methylation data is more suitable to establish models than RNA data. In this study, an ANN system based on DNA methylation data was constructed and showed a potential value in predicting the fraction of M1 in LUAD, which could help to further understand the TME and identify patients that would benefit from immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2263P - Ethnicity-specific distribution of BRCA1, BRCA2, PALB2 and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus
Presenter: Evgeny Imyanitov
Session: Poster session 08
2264P - Proteomics-based phenotypic classification of non-smallcell lung cancer
Presenter: Olena Berkovska
Session: Poster session 08
2265P - miR-4487 enhances gefitinib-mediated ubiquitination and autophagic degradation of EGFR in non-small cell lung cancer cells by targeting USP37
Presenter: Sei-Hoon Yang
Session: Poster session 08
2266P - IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort
Presenter: Marie Morfouace
Session: Poster session 08
2267P - Coronary heart disease and risk of lung cancer: A two-sample Mendelian randomization study
Presenter: Cai Chen Li
Session: Poster session 08
2269P - Patient derived xenografts generated from circulating cancer stem cells on chorioallantoic membrane as an alternative pre-clinical model for personalized medicine in pancreatic cancer
Presenter: Monika Pizon
Session: Poster session 08
2270P - Integrative analyses of bulk and single-cell RNA-seq identified diabetes mellitus-related signature as a prognostic factor in pancreatic adenocarcinoma
Presenter: Le Tang
Session: Poster session 08
2271P - Development of an oncolytic virus for the treatment of high grade serous ovarian cancer and other stromal rich tumours
Presenter: Miriam Bazan Peregrino
Session: Poster session 08
2272P - Minimal DNA-methylation (DNAm) signatures for non-invasive tumor-agnostic estimation of tumor content (TC) and molecular subtype in patients (pts) with metastatic breast cancer (mBC)
Presenter: Matteo Benelli
Session: Poster session 08
2273P - Influence of body mass index (BMI) on the response to chemotherapy in patients with HER2+ breast cancer: Role of the leptin axis
Presenter: Marta González Rodríguez
Session: Poster session 08